Physician profile
Noel E Lasala
NPI 1386646172
$7,015.41
in general payments reported to CMS, 2019-2025
35 companies · $14.42 in 2025
The $14.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $611 · 2021: $2,074 · 2022: $1,883 · 2023: $1,427 · 2024: $878 · 2025: $14.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $883.53 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $797.14 | 2020-2023 | Invega Sustenna, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.06 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $626.28 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $620.04 | 2020-2023 | |
| Lilly USA, LLC | $449.53 | 2020-2023 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $423.66 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $382.55 | 2021-2024 | |
| Amgen INC. | $237.45 | 2020-2024 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $227.19 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.93 | 2022-2024 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $137.77 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $124.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $116.23 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.68 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.21 | 2022-2024 | Eliquis |
| Dexcom, INC. | $104.84 | 2021 | |
| Xeris Pharmaceuticals, INC. | $102.41 | 2022-2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $89.22 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.84 | 2022 | |
| Exact Sciences Corporation | $76.00 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $46.43 | 2019-2020 | |
| Amarin Pharma, INC. | $42.97 | 2022 | |
| Cranial Technologies, INC | $32.09 | 2024-2025 | Doc Band |
| Phadia US INC. | $31.51 | 2022-2023 | Immunocap |
| Astellas Pharma US INC | $30.60 | 2024 | Veozah |
| Azurity Pharmaceuticals, INC. | $30.41 | 2023 | Edarbi, Horizant |
| Otsuka America Pharmaceutical, INC. | $28.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.15 | 2023 | Seglentis, Livalo |
| Inspire Medical Systems, INC. | $25.00 | 2023 | Inspire |
| Horizon Therapeutics Plc | $24.26 | 2023 | Krystexxa |
| Ironwood Pharmaceuticals, INC | $21.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.14 | 2021 | |
| Gilead Sciences, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Lasala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.